All In Biotech

Drug Trial Radar · NCT00843492

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury

Last checked: Nov 20, 2026Latest source record: Mar 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,351 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,351

Actual

Start

Dec 2008

Primary completion

Jan 2010

Study completion Jun 2010

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by ultrasound, and pulmonary embolism (blood clots that migrate to the lungs) in patients with leg injuries below the knee that require a cast or other type of immobilization but not surgery.

Conditions

  • Thrombosis, Venous

Interventions

  • Fondaparinux sodiumDrug

    After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.

  • NadroparinDrug

    After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete MobilizationTime frame: Day 1 to complete mobilization plus 2 days (average of 35.9 study days)

Locations

122 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Agen, France

  • GSK Investigational Site

    Angers, France

  • GSK Investigational Site

    Antony, France

  • GSK Investigational Site

    Argenteuil, France

  • GSK Investigational Site

    Beauvais, France

  • GSK Investigational Site

    Bobigny, France

  • GSK Investigational Site

    Brest, France

  • GSK Investigational Site

    Cergy-Pontoise, France

  • GSK Investigational Site

    Clermont-Ferrand, France

  • GSK Investigational Site

    Colmar, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Grenoble, France

  • GSK Investigational Site

    Lille, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Mougins, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Orthez, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Pringy, France

  • GSK Investigational Site

    Rennes, France

  • GSK Investigational Site

    Roanne, France

  • GSK Investigational Site

    Rouen, France

  • GSK Investigational Site

    Saint-Pierre, France

  • GSK Investigational Site

    Sainte Colombe Les Vienne, France

  • GSK Investigational Site

    Saintes, France

  • GSK Investigational Site

    Toulouse, France

  • GSK Investigational Site

    Valenciennes, France

  • GSK Investigational Site

    Heidelberg, Baden-Wurttemberg, Germany

  • GSK Investigational Site

    Erlangen, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • GSK Investigational Site

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • GSK Investigational Site

    Wiesbaden, Hesse, Germany

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.